Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that the Company presented a poster at the TSC International Research Co ...

License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 3 ...

As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bo ...

Core Viewpoint - Cassava Sciences, Inc. announces the retirement of Chief Medical Officer James W. Kupiec, MD, effective May 9, 2025, and the appointment of Jack Moore, PhD, as Senior Vice President of Clinical Development, effective April 28, 2025, to advance the clinical evaluation of simufilam for CNS disorders, including TSC-related epilepsy [1][3][8] Company Leadership Changes - James W. Kupiec, MD, retires after a notable career in Alzheimer's disease drug development, contributing to high-quality clinical trials at Cassava [2] - Jack Moore, PhD, brings extensive experience in CNS drug development and will focus on advancing simufilam in new indications [3][4] Clinical Development Focus - Dr. Moore will be responsible for the clinical evaluation of simufilam, targeting TSC-related epilepsy and exploring additional applications [3][5] - The company aims to identify potential clinical collaborators and study sites as part of its strategy for the TSC program [4] Background of Jack Moore - Jack Moore has a strong background in biopharmaceuticals, with experience in CNS and neurodegenerative diseases, having held leadership roles at major pharmaceutical companies [6] - He holds a PhD in Neuroscience and has a history of engaging with key opinion leaders and patient advocacy groups [7] Company Overview - Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing investigational treatments for CNS disorders, including simufilam, which targets the filamin A protein [8]